{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:33:46Z","timestamp":1787531626876,"version":"build-2736575974"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regulatory Toxicology and Pharmacology"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.yrtph.2019.04.022","type":"journal-article","created":{"date-parts":[[2019,4,27]],"date-time":"2019-04-27T10:54:03Z","timestamp":1556362443000},"page":"81-89","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Medical devices biocompatibility assessment on HCE: Evidences of delayed cytotoxicity of preserved compared to preservative free eye drops"],"prefix":"10.1016","volume":"106","author":[{"given":"Marisa","family":"Meloni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Balzaretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ceriotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yrtph.2019.04.022_bib1","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s00204-013-1156-8","article-title":"Retrospective analysis of the Draize test for serious eye damage\/eye irritation: importance of understanding the in vivo endpoints under UN GHS\/EU CLP for the development and evaluation of in vitro test methods","volume":"88","author":"Adriaens","year":"2014","journal-title":"Arch. Toxicol."},{"issue":"1","key":"10.1016\/j.yrtph.2019.04.022_bib2","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/IJG.0b013e3181fc8129","article-title":"Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost","volume":"21","author":"Aihara","year":"2012","journal-title":"J. Glaucoma"},{"key":"10.1016\/j.yrtph.2019.04.022_bib3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.tiv.2015.11.012","article-title":"Multi-laboratory validation of SkinEthic HCE test method for testing serious eye damage\/eye irritation using liquid chemicals","volume":"31","author":"Al\u00e9p\u00e9e","year":"2016","journal-title":"Toxicol. Vitro"},{"key":"10.1016\/j.yrtph.2019.04.022_bib4","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.tiv.2016.02.014","article-title":"Multi-Laboratory evaluation of SkinEthic HCE test method for testing serious eye damage\/eye irritation using solid chemicals and overall performance of the test method with regard to solid and liquid chemicals testing","volume":"34","author":"Al\u00e9p\u00e9e","year":"2016","journal-title":"Toxicol. Vitro"},{"issue":"6","key":"10.1016\/j.yrtph.2019.04.022_bib5","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s12325-011-0029-x","article-title":"Effects of benzalkonium chloride- and polyquad-preserved combination glaucoma medications on cultured human ocular surface cells","volume":"28","author":"Ammar","year":"2011","journal-title":"Adv. Ther."},{"key":"10.1016\/j.yrtph.2019.04.022_bib6","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/j.1755-3768.2008.01250.x","article-title":"Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma","volume":"86","author":"Baudouin","year":"2008","journal-title":"Acta Ophthalmol."},{"issue":"4","key":"10.1016\/j.yrtph.2019.04.022_bib7","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.preteyeres.2010.03.001","article-title":"Preservatives in eyedrops: the good, the bad and the ugly","volume":"29","author":"Baudouin","year":"2010","journal-title":"Prog. Retin. Eye Res."},{"issue":"3","key":"10.1016\/j.yrtph.2019.04.022_bib8","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1089\/jop.2010.0111","article-title":"In vitro comparative toxicology of polyquad-preserved and benzalkonium chloride-preserved travoprost\/timolol fixed combination and latanoprost\/timolol fixed combination","volume":"27","author":"Brignole-Baudouin","year":"2011","journal-title":"J. Ocul. Pharmacol. Ther."},{"issue":"8","key":"10.1016\/j.yrtph.2019.04.022_bib9","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1016\/j.tiv.2013.08.006","article-title":"In vitro human skin irritation test for evaluation of medical device extracts","volume":"27","author":"Casas","year":"2013","journal-title":"Toxicol. Vitro"},{"issue":"2","key":"10.1016\/j.yrtph.2019.04.022_bib10","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1089\/aivt.2015.0007","article-title":"Evaluation of an in vitro human dermal sensitization test for use with medical device Extracts","volume":"1","author":"Coleman","year":"2015","journal-title":"Appl. In Vitro Toxicol."},{"issue":"1","key":"10.1016\/j.yrtph.2019.04.022_bib11","first-page":"2","article-title":"Preservatives from the eye drops and the ocular surface","volume":"59","author":"Coroi","year":"2015","journal-title":"Rom. J. Ophthalmol."},{"issue":"3","key":"10.1016\/j.yrtph.2019.04.022_bib12","first-page":"642","article-title":"Quaternary ammoniums and other preservatives' contribution in oxidative stress and apoptosis on chang conjunctival cells","volume":"42","author":"Debbasch","year":"2001","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"issue":"December 2017","key":"10.1016\/j.yrtph.2019.04.022_bib13","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.tiv.2018.01.001","article-title":"Round robin study to evaluate the reconstructed human Epidermis (RhE) model as an in vitro skin irritation test for detection of irritant activity in medical device Extracts","volume":"50","author":"De Jong","year":"2018","journal-title":"Toxicol. Vitro"},{"issue":"4","key":"10.1016\/j.yrtph.2019.04.022_bib14","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.tiv.2005.09.005","article-title":"Reconstituted human corneal epithelium: a new alternative to the Draize eye test for the assessment of the eye irritation potential of chemicals and cosmetic products","volume":"20","author":"Doucet","year":"2006","journal-title":"Toxicol. Vitro"},{"issue":"3","key":"10.1016\/j.yrtph.2019.04.022_bib15","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.etp.2016.12.002","article-title":"Comparison of the effects of various lubricant eye drops on the in vitro rabbit corneal healing and toxicity","volume":"69","author":"Dutescu","year":"2017","journal-title":"Exp. Toxicol. Pathol."},{"issue":"1","key":"10.1016\/j.yrtph.2019.04.022_bib16","first-page":"59","article-title":"Preservatives in topical ophthalmic medications: historical and clinical perspectives","volume":"4","author":"Freeman","year":"2009","journal-title":"Expert Reviews Ltd"},{"issue":"1","key":"10.1016\/j.yrtph.2019.04.022_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/OPTH.S24983","article-title":"First experience with BAK-free travoprost 0.004% in topical glaucoma medication","volume":"6","author":"Gado","year":"2011","journal-title":"Clin. Ophthalmol."},{"issue":"1","key":"10.1016\/j.yrtph.2019.04.022_bib18","doi-asserted-by":"crossref","first-page":"34","DOI":"10.5301\/ejo.5000001","article-title":"Comparison of a travoprost BAK-free formulation preserved with polyquaternium-1 with BAK-preserved travoprost in ocular hypertension or open-angle glaucoma","volume":"22","author":"Gandolfi","year":"2012","journal-title":"Eur. J. Ophthalmol."},{"key":"10.1016\/j.yrtph.2019.04.022_bib19","series-title":"JS TFOS DEWS II Iatrogenic Report the Ocular Surface","first-page":"516","author":"Gomes","year":"2017"},{"issue":"9","key":"10.1016\/j.yrtph.2019.04.022_bib20","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1089\/jop.2014.0030","article-title":"In vitro effects of preserved and unpreserved anti-allergic drugs on human corneal epithelial cells","volume":"30","author":"Guzman-Aranguez","year":"2014","journal-title":"J. Ocul. Pharmacol. Ther.: Off. J. Assoc. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.yrtph.2019.04.022_bib21","doi-asserted-by":"crossref","first-page":"43","DOI":"10.14573\/altex.2010.1.43","article-title":"First alternative method validated by a retrospective weight-of-evidence ap- proach to replace the Draize eye test for the identification of non-irritant substances for a defined applicability domain","volume":"27","author":"Hartung","year":"2010","journal-title":"ALTEX"},{"issue":"3","key":"10.1016\/j.yrtph.2019.04.022_bib22","first-page":"613","article-title":"Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy","volume":"2","author":"Henry","year":"2008","journal-title":"Clin. Ophthalmol."},{"issue":"1","key":"10.1016\/j.yrtph.2019.04.022_bib23","first-page":"291","article-title":"Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients","volume":"3","author":"Horsley","year":"2009","journal-title":"Clin. Ophthalmol."},{"issue":"3","key":"10.1016\/j.yrtph.2019.04.022_bib24","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/ICO.0b013e31815cf651","article-title":"Comparison of corneal and conjunctival changes after dosing of travoprost preserved with SofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears","volume":"27","author":"Kahook","year":"2008","journal-title":"Cornea"},{"issue":"1","key":"10.1016\/j.yrtph.2019.04.022_bib25","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.2147\/OPTH.S14113","article-title":"Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost","volume":"4","author":"Katz","year":"2010","journal-title":"Clin. Ophthalmol."},{"issue":"4","key":"10.1016\/j.yrtph.2019.04.022_bib26","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1089\/jop.2006.22.267","article-title":"Comparison of toxicological profiles of benzalkonium chloride and polyquaternium-1: an experimental study","volume":"22","author":"Labb\u00e9","year":"2006","journal-title":"J. Ocul. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.yrtph.2019.04.022_bib27","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1136\/bjo.2010.189449","article-title":"Toxicological evaluation of preservative-containing and preservative-free topical prostaglandin analogues on a three-dimensional-reconstituted corneal epithelium system","volume":"95","author":"Liang","year":"2011","journal-title":"Br. J. Ophthalmol."},{"issue":"4","key":"10.1016\/j.yrtph.2019.04.022_bib28","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s12325-009-0023-8","article-title":"A randomized clinical comparison of OPTI-FREE EXPRESS and ReNu MultiPLUS multipurpose lens care solutions","volume":"26","author":"Lipener","year":"2009","journal-title":"Adv. Ther."},{"issue":"4","key":"10.1016\/j.yrtph.2019.04.022_bib29","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3109\/15569527.2012.667031","article-title":"An in vitro method for detecting chemical sensitization using human reconstructed skin models and its applicability to cosmetic, pharmaceutical, and medical device safety testing","volume":"31","author":"McKim","year":"2012","journal-title":"Cutan. Ocul. Toxicol."},{"key":"10.1016\/j.yrtph.2019.04.022_bib30","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.yrtph.2009.04.004","volume":"54","author":"McNamee","year":"2009","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"3","key":"10.1016\/j.yrtph.2019.04.022_bib31","doi-asserted-by":"crossref","first-page":"275","DOI":"10.14573\/altex.1807041","article-title":"Animal testing and its alternatives \u2013 the most important Omics is Economics","volume":"35","author":"Meigs","year":"2018","journal-title":"ALTEX"},{"issue":"1","key":"10.1016\/j.yrtph.2019.04.022_bib32","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.tiv.2009.08.016","article-title":"Occludin gene expression as an early in vitro sign for mild eye irritation assessment","volume":"24","author":"Meloni","year":"2010","journal-title":"Toxicol. Vitro"},{"key":"10.1016\/j.yrtph.2019.04.022_bib33","first-page":"1433","article-title":"Corneal epithelial toxicity of antiglaucoma formulations: in vitro study of repeated applications","volume":"6","author":"Meloni","year":"2012","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.yrtph.2019.04.022_bib34","article-title":"Toxicity potential of eye drops with soft preservatives versus non-preserved on human corneal epithelium","author":"Meloni","year":"2017","journal-title":"Poster ARVO"},{"key":"10.1016\/j.yrtph.2019.04.022_bib35","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/BF02849799","article-title":"Evaluation of the comfort of Alphagan P compared to Alphagan in irritated eyes","volume":"20","author":"Mundorf","year":"2003","journal-title":"Adv. Ther."},{"key":"10.1016\/j.yrtph.2019.04.022_bib36","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.2147\/OPTH.S160053","article-title":"Real-life results of switching from preserved to preservative-free arti cial tears containing hyaluronate in patients with dry eye disease","volume":"12","author":"Nasser","year":"2018","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.yrtph.2019.04.022_bib37","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2147\/OPTH.S126042","article-title":"Switching to preservative-free latanoprost: impact on tolerability and patient satisfaction","volume":"11","author":"Negrete","year":"2017","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.yrtph.2019.04.022_bib38","series-title":"Env\/Jm\/Mono(2017)15 Guidance Document on an Integrated Approach on Testing and Assessment (IATA) for Serious Eye Damage and Eye Irritation Series on Testing & Assessment No. 263","year":"2017"},{"issue":"4","key":"10.1016\/j.yrtph.2019.04.022_bib39","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1167\/iovs.08-2992","article-title":"Multiple endpoint Analysis of the 3d-reconstituted corneal epithelium after treatment with benzalkonium chloride: early detection of toxic damage","volume":"50","author":"Pauly","year":"2009","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"issue":"February","key":"10.1016\/j.yrtph.2019.04.022_bib40","first-page":"745","article-title":"Multiple endpoint Analysis of BAC-preserved and unpreserved antiallergic eye drops on a 3d-reconstituted corneal epithelial model","volume":"17","author":"Pauly","year":"2011","journal-title":"Mol. Vis."},{"key":"10.1016\/j.yrtph.2019.04.022_bib41","first-page":"8172","volume":"vol. 53","author":"Pauly","year":"2012"},{"issue":"2","key":"10.1016\/j.yrtph.2019.04.022_bib42","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ajo.2015.04.041","article-title":"Polyquaternium-1-Preserved travoprost 0.003% or benzalkonium chloride-preserved travoprost 0.004% for glaucoma and ocular hypertension","volume":"160","author":"Peace","year":"2015","journal-title":"Am. J. Ophthalmol."},{"issue":"5","key":"10.1016\/j.yrtph.2019.04.022_bib43","doi-asserted-by":"crossref","first-page":"379","DOI":"10.5301\/ejo.5000593","article-title":"Comparison of the lubricant eyedrops Optive\u00ae, vismed Multi\u00ae, and Cationorm\u00ae on the corneal healing process in an ex vivo model","volume":"25","author":"Pinheiro","year":"2015","journal-title":"Eur. J. Ophthalmol."},{"issue":"5","key":"10.1016\/j.yrtph.2019.04.022_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096448","article-title":"Development of a curved, stratified, in vitro model to assess ocular biocompatibility","volume":"9","author":"Postnikoff","year":"2014","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.yrtph.2019.04.022_bib45","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1517\/17425247.2011.617736","article-title":"Ophthalmic preservatives: focus on polyquaternium-1","volume":"8","author":"Rolando","year":"2011","journal-title":"Expert Opin. Drug Deliv."},{"issue":"3","key":"10.1016\/j.yrtph.2019.04.022_bib46","doi-asserted-by":"crossref","first-page":"296","DOI":"10.5301\/ejo.5000220","article-title":"Risk factors to develop ocular surface disease in treated glaucoma or ocular hypertension patients","volume":"23","author":"Rossi","year":"2012","journal-title":"Eur. J. Ophthalmol."},{"issue":"2","key":"10.1016\/j.yrtph.2019.04.022_bib47","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/bjophthalmol-2012-302121","article-title":"Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma","volume":"97","author":"Rouland","year":"2013","journal-title":"Br. J. Ophthalmol."},{"issue":"4","key":"10.1016\/j.yrtph.2019.04.022_bib48","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1167\/iovs.16-20903","article-title":"The eye drop preservative benzalkonium chloride potently induces mitochondrial dysfunction and preferentially affects LHON mutant cells","volume":"58","author":"Sandipan","year":"2017","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"issue":"1","key":"10.1016\/j.yrtph.2019.04.022_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2011.05.033","article-title":"Ocular surface disease and quality of life in patients with glaucoma","volume":"153","author":"Skalicky","year":"2012","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.yrtph.2019.04.022_bib50","first-page":"741","article-title":"Results of a validation study in Germany on two in vitro alternatives to the Draize eye irritation test, the HET-CAM test and the 3T3 NRU cytotoxicity test","volume":"24","author":"Spielmann","year":"1996","journal-title":"ALTA"},{"issue":"11","key":"10.1016\/j.yrtph.2019.04.022_bib51","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1136\/bjophthalmol-2017-311544","article-title":"Preservatives in glaucoma medication","volume":"102","author":"Steven","year":"2018","journal-title":"Br. J. Ophthalmol."},{"issue":"3","key":"10.1016\/j.yrtph.2019.04.022_bib52","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.sjopt.2014.06.006","article-title":"Balancing antimicrobial efficacy and toxicity of currently available topical ophthalmic preservatives","volume":"28","author":"Tu","year":"2014","journal-title":"Saudi J. Ophthalmol."},{"issue":"7","key":"10.1016\/j.yrtph.2019.04.022_bib53","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jfo.2010.06.018","article-title":"Les conservateurs des collyres: vers une prise de Conscience de Leur toxicit\u00e9","volume":"33","author":"Vaede","year":"2010","journal-title":"J. Fr. Ophtalmol."},{"key":"10.1016\/j.yrtph.2019.04.022_bib54","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.tox.2014.11.003","article-title":"An overview of current techniques for ocular toxicity testing","volume":"327","author":"Wilson","year":"2015","journal-title":"Toxicology"},{"key":"10.1016\/j.yrtph.2019.04.022_bib55","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.tiv.2016.09.001","article-title":"Exploration and comparison of in vitro eye irritation tests with the ISO standard in vivo rabbit test for the evaluation of the ocular irritancy of contact lenses","volume":"37","author":"Yun","year":"2016","journal-title":"Toxicol. Vitro"}],"container-title":["Regulatory Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230019301217?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230019301217?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T11:49:06Z","timestamp":1577188146000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0273230019301217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":55,"alternative-id":["S0273230019301217"],"URL":"https:\/\/doi.org\/10.1016\/j.yrtph.2019.04.022","relation":{},"ISSN":["0273-2300"],"issn-type":[{"value":"0273-2300","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medical devices biocompatibility assessment on HCE: Evidences of delayed cytotoxicity of preserved compared to preservative free eye drops","name":"articletitle","label":"Article Title"},{"value":"Regulatory Toxicology and Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yrtph.2019.04.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}